AbbVie, Teneobio partner on Multiple Myeloma

Feb 11, 2019

AbbVie and Teneobio announced a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

TNB-383B is Teneobio's first clinical candidate, which works by targeting BCMA using the California-based biotech's unique T-cell redirecting platform.

According to AbbVie, Teneobio's novel approach to T-cell redirection with TNB-383B "has the potential to be a treatment option that may offer new hope for myeloma patients."

Under the terms of the agreement, Teneobio affiliate TeneoOne will receive an upfront payment of $90 million and will continue developing TNB-383B through Phase 1. AbbVie will hold the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B.

Read the press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments